OssDsign is a Sweden-based biotechnology and healthcare company founded in 2011. The company focuses on developing and globally providing next-generation orthobiologics products. By leveraging cutting-edge material science, OssDsign aims to support the body's natural healing capabilities, thereby restoring patients' quality of life. The company recently secured a significant kr150.00M post-IPO equity investment on 26 September 2023. OssDsign's commitment to innovation and its ability to address unmet medical needs make it an intriguing opportunity for venture capital firms seeking to invest in the burgeoning biotechnology sector. With its clear vision and recent financial backing, OssDsign is well-positioned to make an impact in the orthobiologics market. For more information, visit their website at www.ossdsign.com.
No recent news or press coverage available for OssDsign .